Suggestions
Marcela Maus
Director of Cellular Immunotherapy, MGH Cancer Center; Professor, Harvard Medical School
Marcela Maus, M.D., Ph.D., is a prominent figure in the field of cellular immunotherapy and cancer research. She currently holds several important positions:
Professional Roles
- Director of Cellular Immunotherapy at the Massachusetts General Hospital (MGH) Cancer Center12
- Associate Professor at Harvard Medical School2
- Paula O'Keefe Chair in Oncology at MGH2
- Attending Physician in the Hematopoietic Cell Transplant and Cell Therapy division of Oncology at MGH2
- Associate Member of the Broad Institute of Harvard and MIT2
- Associate Member of the Ragon Institute of MGH, MIT, and Harvard2
Research Focus
Dr. Maus is internationally recognized for her work as a translational physician-scientist in immunology, particularly in the development of T-cell immunotherapies for cancer treatment. Her laboratory focuses on:
- Studying the biology of human T cell activation, co-stimulation, and memory2
- Developing new forms of chimeric antigen receptors (CARs) for treating hematologic malignancies and solid tumors1
- Translating laboratory findings into clinical trials for cancer patients3
Education and Training
- Undergraduate studies at Massachusetts Institute of Technology (MIT)2
- M.D. and Ph.D. from the University of Pennsylvania2
- Internal medicine training at the University of Pennsylvania1
- Hematology and medical oncology training at Memorial Sloan Kettering Cancer Center1
Achievements and Contributions
Dr. Maus has authored over 100 papers indexed in PubMed and holds multiple NIH R01 grants and several Investigational New Drug Applications (INDs).2 She established the Maus Lab in 2015, which is located at the Charlestown Navy Yard campus of Massachusetts General Hospital.3
Her work has led to significant advancements in cellular immunotherapy, including the development of novel CAR T-cell therapies for various types of cancer, such as glioblastoma.45
Highlights
As you’ve likely seen from my team, we are entering the summer intent on expanding our clinical research aroundCAR-T therapy, which resulted in "dramatic and rapid" regression of glioblastoma in our Phase 1 study. No cancer center can make research-based advances like this without the support of public and private sector partners. That’s why I’m eager to meet this week with Members of Congress to reinforce the significant impact NIH has on advancing science. With the help of NIH research grants over the course of many years, we are exploring new frontiers in treatment using CAR-T, CRISPR and other therapeutics. It’s clear that sustained support is necessary to discover new, more effective treatments for patients. https://lnkd.in/eUWHPEXt
